TTP LabTech Delivers Automated Chemistry System for Salt and Polymorph Screening to AstraZeneca
News Jan 28, 2009
TTP LabTech announced that it had successfully completed a major laboratory automation project with AstraZeneca. The project, which took over three years to complete, involved the design and build of a fully automated system for salt and polymorph screening of novel compounds.
The system completed its site acceptance test (SAT) late last year before coming on-line at AstraZeneca’s research facility in Sodertalje.
This system for synthesizing and analyzing crystalline materials was designed in partnership between AstraZeneca and TTP LabTech. The overall objectives were to increase throughput, to explore experimental space and to automate the analysis of huge amounts of data.
The project has been undertaken in stages, the first of which was a prototyping stage. This stage helped to minimize risk by tackling those design elements that carried the greatest number of unknowns early in the project.
The next stage was the full design and build of a single screening machine to demonstrate control, functionality, and consistency of the basic automated polymorph screening processes. Now TTP LabTech has been asked to replicate the entire system in order to double the overall throughput.
New Chemical Synthesis Process: Synergy of Two Catalysts in One FlaskNews
Researchers report the one-step synthesis of a ketone from an aldehyde by the combination of thiazolium N-heterocyclic carbene and palladium/bisphosphine catalysts in one flask. The two catalysts function in a synergistic manner. This study is expected to lead to new synthesis processes of precursor compounds for medications.READ MORE
Synthesis of Drug-Like Molecules Simplified Using New Cross-Coupling MethodNews
Researchers have designed a new molecule-building method. The technique, described recently in the journal Science, paves the way toward other new chemical reactions and facilitates the synthesis of pharmaceutically-relevant molecules.READ MORE
Domainex Appoints Dr Bodo Spori as Head of Business Development for EuropeNews
Domainex Ltd, a privately-owned drug discovery services company, is pleased to announce the appointment of Dr Bodo Spori as Head of Business Development for Europe.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Pharmacy and Clinical Research
Jul 16 - Jul 17, 2018